NCT01815346 is a Phase 1, PHASE2 clinical trial of Acupuncture in Breast Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT01815346?

NCT01815346 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01815346?

Interventions in NCT01815346: Acupuncture, Questionnaires, Hand Function and Balance Tests.

What condition does NCT01815346 study?

NCT01815346 studies Breast Cancer.

Is NCT01815346 still recruiting?

NCT01815346 is currently terminated. Last updated 12 January 2018.

Last reviewed 2018-01-12 · How we verify

NCT01815346

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acupuncture Chemotherapy-Induced Peripheral Neuropathy (CIPN) IRG

Terminated Phase 1, PHASE2 Last updated 12 January 2018

What this trial tests

Phase 1, PHASE2 trial testing Acupuncture in Breast Cancer in 4 participants. Terminated before completion.

Timeline

6 July 2014

Primary endpoint
10 May 2016

10 May 2016

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	6 July 2014
Primary completion	10 May 2016
Estimated completion	10 May 2016
Sites	1 location across United States

Drugs / interventions tested

Acupuncture — full drug profile →
Questionnaires
Hand Function and Balance Tests

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to compare the level of effectiveness for 2 acupuncture treatment schedules for chronic CIPN in breast cancer survivors. Researchers also want to study how patients may respond to acupuncture treatments, and how the treatments may affect quality of life, hand function, balance, and the use of drugs for neuropathy pain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Acupuncture

Trials testing the same drug.

NCT07522567 — Efficacy of Acupuncture on Chronic Tinnitus and Its Association With Auditory Brainstem Response Measures · NA · not yet recruiting
NCT07575334 — Acupuncture Therapy for Sudden Sensorineural Hearing Loss · NA · recruiting
NCT07522710 — Clinical Study on Intensive Multi-acupuncture in the Treatment of Neck and Shoulder Myofascial Pain Syndrome · NA · not yet recruiting
NCT07505927 — Acupuncture for Postoperative Gastric Emptying Delay · NA · not yet recruiting
NCT07410793 — Acupuncture With Chinese Herbal Cream Compare With Acupuncture With Calcipotriol in Plaque Psoriasis. · Phase 2 · recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01815346 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 12 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01815346.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing